Screening for EGFR mutations in lung cancer.
Certain mutations in the epidermal growth factor receptor (EGFR) gene confer hypersensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with advanced non-small cell lung cancer. Large-scale screening for EGFR mutations in such patients is feasible for predicting response to TKIs and thus guiding treatment.
Molina-Vila
Miguel A
MA
Medical Oncology Service, Pangaea Biotech, USP Institut Universitari Dexeus, Barcelona, Catalunya, Spain.
Bertran-Alamillo
Jordi
J
Mayo
Clara
C
Rosell
Rafael
R
D066246:ErbB Receptors / Q000097:blood / Q000235:genetics*; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000235:genetics*; D009154:Mutation / Q000235:genetics*; D016133:Polymerase Chain Reaction
D066246:ErbB Receptors